Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dosereduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not eligible for standard transplant procedures, were included. The 5-day conditioning therapy consisted of 3.3 mg/kg intravenous busulphan × 2 days and 30 mg/m 2 fludarabine × 5 days. GVHD prophylaxis was performed with either CsA alone (n = 5), CsA combined with short course methotrexate (n = 5) or mycophenolate mofetil (n = 14). The day 100 survival was 95.2% for the whole group. All patients engrafted after a median of 15 days (range, 11-19) and 12.5 days (range, 10-19) for neutrophils and platelets, respectively. The median time to a neutrophil count of Ͻ0.5 × 10 9 /l was 7 days (range, 2 to 12). Acute GVHD ϾI was observed in six patients, whereas eight patients have signs of chronic GVHD. The prospective 12 month overall survival with a median follow-up of 7 months is 63%. Relapse of disease and toxicity associated with chronic GVHD were the main causes of death. The treatment-related mortality was 12.5%. Dose-reduced conditioning using intravenous busulphan and fludarabine allows stable engraftment without ATG in related transplants and leads to a reduction of transplant-related mortality. Bone Marrow Transplantation (2000) 26, 119-125.
eneic bone marrow transplantation (BMT). Prolonged remission can be achieved by donor leukocyte infusions in 70 to 80% of patients with relapsing chronic myeloid leukemia.
1,2 Therefore, the success of allogeneic BMT seems to depend mostly on graft-versus-tumor effects which can also be obtained after less intensive preparative regimens when persistent hematopoietic chimerism is achieved.
There are several reports in the literature on the establishment of mixed lymphohematopoietic chimerism after nonmyeloablative radio-/chemotherapy in animal models. 3, 4 Encouraging clinical results have been achieved by using reduced doses of alkylating agents together with purine analogues for conditioning therapy. 5, 6 Recently, stable engraftment was achieved in patients after 200 rad total body irradiation (TBI) combined with immunosuppressive drugs. 7 The protocol pioneered by Slavin et al 5 contained antithymocyte globulin (ATG) as an immunosuppressive agent. Since we felt that ATG was an expensive compound with varying biological activities between batches, we tried to simplify the original protocol by combining a reduced 5-day schedule of fludarabine and intravenous busulphan without additional ATG. The primary end-points were rate and durability of engraftment and early extramedullary toxicity. As described in this paper, we observed successful engraftment in recipients of blood stem cell grafts from HLA identical siblings after dose-reduced conditioning without ATG. Prolonged remissions were achieved in patients with limited tumor burdens at the time of transplant. Graft-versus-tumor effects were observed in a patient with renal cell carcinoma.
Patients and methods
Twenty-four patients were included after having given informed consent from May 1998 to October 1999. The study had been approved by the local ethical board. Only patients not eligible for standard allogeneic blood stem cell transplantation were included. Table 1 gives an overview of the patients' characteristics and outcome as of 21 February 2000 grouped according to diseases. As shown in Table 1 , most patients belonged to a high-risk category with either a reduced performance status or extensive pretreatment. The mean Karnofsky score by the time of transplantation was 75% (range, 50-100%). The median age for the whole group was 47 years (range, 25-65). The pretreatment s-AML = secondary AML; CMMoL = chronic myelomonocytic leukemia, lymphoma; RCC = renal cell carcinoma; SCLC = small cell lung cancer; NA = not available; CR/PR = complete/partial remission; CP = chronic phase; AP = accelerated phase; PD = progressive disease.
had included between one and five cycles of chemotherapy (CT). Two patients (UPN 128 and 248) had undergone high-dose chemotherapy with autologous stem cell transplantation. Invasive aspergillosis had occurred during pretreatment in four out of 24 patients. Three patients with solid tumors were included (one renal cell carcinoma, one small cell lung cancer and one Ewing's sarcoma).
HLA matching
All patients and their sibling donors were tested serologically for HLA-A and B and with high-resolution PCR-SSOP typing for HLA-C, DRB1 and DQB1 according to standard procedures. 8 
Stem cell collection
All patients except UPN 337 received unmanipulated PBSC from matched sibling donors. Since the donor for this patient UPN 337 declined to donate PBSC, bone marrow was harvested after informed consent under general anesthesia. In all other donors, mobilization of PBSC was performed using 7.5 g/ml lenograstim or 10 g/kg filgrastim for 5 days. Cells were collected with one or two aphereses on days 5 and 6 of the stimulation period. The product was cryopreserved when indicated. Bone marrow was infused without prior manipulation.
Chemotherapy
Conditioning therapy started with 3.3 mg/kg busulphan i.v.
(Sigma-Aldrich, Deisenhofen, Germany) dissolved in 10 ml of dimethyl sulphoxide and further diluted with 1000 ml saline. The single daily dose was infused over 3 h on day −6 and −5. The pharmacokinetic data in animals for this formulation have been published. 9 Subsequent studies in humans have shown 3.3 mg/kg i.v. to be equivalent to 4 mg/kg busulphan given orally in a single dose (data not shown). Fludarabine (Medak, Munich, Germany) was infused at a single dose of 30 mg/m 2 over 30 min from day −6 to day −2.
Supportive care
Patients were treated in single or double rooms. All patients received antibacterial and antifungal prophylaxis with ciprofloxacine at 500 mg twice daily and fluconazole at 200 mg per day. Acyclovir was given at 1200 mg daily in patients with positive herpes simplex virus IgG titers. Patients with negative CMV IgG titers received blood products from CMV seronegative donors. The serostatus of patients and donors is provided in Table 2 . Bacterial and fungal surveillance cultures were performed every second week. Broad spectrum antibiotics were begun whenever body temperature increased above 38.5°C, C-reactive protein increased significantly or when a positive finding was made on chest X-ray. PCR for CMV DNA and pp65 antigen testing in peripheral blood were performed once weekly. Hemoglobin was maintained at a level of Ͼ5 mmol/l and the platelet count was maintained at Ͼ20 × 10 9 /l with in-line filtered and irradiated blood products. cells/kg; MMF = mycophenolate mofetil; Take N = Neutrophils Ͼ500/l, P = platelets Ͼ50 000/l; RBC = units of packed RBC; Plts = thrombopheresis units; NA = not applicable.
GVHD prophylaxis
GVHD prophylaxis was performed with 3 mg/kg cyclosporine (CsA) i.v. starting 1 day before the infusion of the graft. Further intravenous or oral dosage was adapted according to CsA trough blood levels. Two patients with high-risk AML (UPN 237 and 350), who were cytopenic when conditioning therapy was started, received only CsA. The same was true for two CLL patients, where the diseasespecific protocol only contained CsA. Additional methotrexate (MTX) 5 mg/m 2 was injected i.v. in the first five recipients on days +1, +3 and +6. Mycophenolate mofetil (MMF) was given p.o. at 4 × 500 mg from day +1 to day +40 instead of MTX to the subsequent 14 patients because the rate of acute GVHD with MTX still seemed to be relatively high and animal data indicated MMF to be useful as graft rejection prophylaxis. 10 Patients developing GVHD were maintained with MMF and received 2 mg/kg/day prednisolone in addition, which was tapered upon clinical response.
Study endpoints
Engraftment, defined as Ͼ0.5 × 10 9 /l ANC for 3 days, Ͼ50 × 10 9 /l platelets without transfusion, and the toxicity of the protocol in this patient cohort were the primary endpoints. Secondary objectives were the antileukemic and antitumor effects and the rate of acute GVHD observed. Organ toxicity was documented according to WHO criteria. Acute and chronic GVHD were graded according to consensus criteria.
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Analysis of chimerism
Samples for chimerism analysis in peripheral blood were drawn twice weekly during hospital stay and weekly in the out-patient department. Chimerism analysis was performed as described recently. 13 In brief, DNA was extracted from peripheral blood samples using a silica-based procedure (QiaAmp DNA blood kit, Qiagen, Hilden, Germany). Multiplex PCR was then performed using the AmpFlSTR Profiler kit (PE Biosystems, Weiterstadt, Germany). High-resolution PAA-gel electropheresis and four-color fluorescence detection were performed on an ABI 377 automated DNA sequencer. For each STR allele, the area under the curve for the corresponding signal is automatically processed by the GeneScan 3.1 software (PE Biosystems). The percentage of donor chimerism was obtained by the following calculation: area signal donor/(area signal donor + area signal recipient). Finally, a mean value was calculated for all informative (different between donor and recipient) alleles. The values are given as percent donor signal.
Statistical analysis
Most quantitative parameters are provided as median or mean with standard deviation. The actuarial overall and event-free survivals were calculated as of 21 February 2000 from the day of transplantation according to the methods of Kaplan and Meier.
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Results
The clinical results for all patients are provided in Tables 1  and 2 .
Toxicity
The maximum WHO toxicity for non-hematological parameters observed in five patients was grade 3. In one patient (UPN 347) neurological toxicity with convulsion and loss of short-term memory occurred on day +30 for a period of 3 weeks. Although viral encephalitis was assumed and antiviral treatment was performed with foscarnet for 2 weeks, no pathogenic agent could be identified. Therefore, the observed toxicity has to be considered as transplantrelated. In three patients grade 3 gastrointestinal toxicity (mucositis and diarrhea) was observed. One patient with Ewing's sarcoma who had received several cycles of platinum-based chemotherapy (UPN 336) showed elevated blood creatinine levels 3 weeks after transplantation. In 19 patients no toxicity Ͼ2 could be documented (grade 0, 4; grade 1, 7; grade 2, 8). One early death caused by CMV pneumonia was observed. Only six patients experienced fever Ͼ38.5°C for a median of 2.5 days (range, 1 to 6 days).
Engraftment
The mean dose of CD34 positive cells × 10 6 /kg infused was 5.71 ± 1.9. Primary neutrophil engraftment with an absolute neutrophil count (ANC) of greater than 0.5 ± 10 9 /l was achieved in all 24 patients at a median of 15 days after transplantation (range 11 to 19 days). Transfusion requirements were low with 4 units of packed RBC (range 0 to 10) and one thrombopheresis product (range 0 to 7) per patient. A platelet count of Ͼ50 × 10 9 /l sustained without transfusion was reached 12.5 days (range 10 to 19) after transplantation. The median number of days with an ANC below 0.5 × 10 9 /l was 7 with a range from 2 to 12, dependent on the underlying disease and pretreatment.
GVHD
Acute GVHD was observed in 14 patients. The median day of occurrence of clinical GVHD was +17. Only six patients had grade II GVHD, which could be controlled with systemic steroids in all cases. Chronic GVHD has been documented in eight out of 24 patients (33%), so far.
Infections and other complications
Pre-emptive therapy for CMV antigenemia had to be started in six patients with positive pp65 antigen testing. CMV pneumonitis was assumed as the cause of death on day +60 in one patient (UPN 261) who had also experienced loss of chimerism preceding hematological relapse. In patient UPN 371 ganciclovir treatment had to be started because of CMV colitis which had been proven by colonoscopy. Her symptoms gradually resolved after 7 days of antiviral therapy. Figure 1 shows the mean values of donor chimerism with standard deviation on days 10, 20, 30, 50, 100 and 150 for patients, who did not relapse during follow-up. The increase of chimerism during the first 3 weeks is somewhat slower and with a higher variability compared to a historic group of patients who had undergone dose-intensive conditioning therapy (manuscript in preparation). Although the increase in donor signals was heterogeneous, all patients with stable engraftment eventually developed complete donor chimerism.
Chimerism
As shown in Figure 2 , decreasing chimerism indicated relapsing disease in four representative patients with hematological malignancies. On the other hand, four patients with small cell lung cancer (UPN 289), Ewing's sarcoma (UPN 336) and Hodgkin's disease (UPN 128, 248) had progressive disease despite stable full donor chimerism.
Relapse and survival
Intermittent clinical responses could be documented in most patients. The day 100 overall (OS) survival for all patients is 95.2%. The Kaplan-Meier plot for OS is depicted in Figure 3 . With a median observation time of 6 months, the expected 12 months OS is 63%. The overall transplant-related mortality was 12.5% (3/24) in this patient group.
Four patients with high-risk leukemia experienced early relapse of disease. Cytogenetic analysis of bone marrow metaphases revealed Ph-negativity in all three patients with CML. Two of these patients (UPN 162, UPN 285) were negative for the BCR/ABL rearrangement by PCR in the peripheral blood and in bone marrow.
In the patient with metastatic renal cell carcinoma (UPN 291) a 40% regression in the size of one representative lesion could be measured in two dimensions. Between the two CT scans acute GVHD grade II-III had occurred. Early evaluation of the patient with Ewing's sarcoma (UPN 336) revealed regression of pulmonary metastases due to the conditioning regimen. Unfortunately, the patient showed 183; b, UPN 328; c, UPN 309; d, UPN 261) . The percentage of donor chimerism vs recipient is provided and the percentage of blasts in bone marrow or peripheral blood are given, whenever available. In patient UPN 261, death due to CMV pneumonia occurred before bone marrow biopsy could be performed. progressive disease 2 months post transplant despite clinical signs of acute GVHD. The same was true for both patients with Hodgkin's disease, in whom progressive lymphoma could be detected shortly after transplantation. In patient UPN 128 interleukin-2 treatment led to acute GVHD but the infiltration of the liver progressed. Both patients are still alive with stable disease receiving chemotherapy with gemcitabine.
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The causes of death were relapsing disease in four patients, CMV pneumonia in one patient (UPN 261) and cerebral stroke or hemorrhage in two patients suffering from chronic GVHD (UPN 291 and 162).
Discussion
Although improvements in supportive treatment have been achieved during the last decade, conventional conditioning therapy and consecutive allogeneic stem cell transplantation is still associated with significant toxicity and early morbidity. 15, 16 Therefore only patients under the age of 55 years with good performance status without prior infectious complications meet the inclusion criteria for most protocols of allogeneic stem cell transplantation. Since the curative potential of allogeneic cell therapy is attractive for many patients with malignant hematological diseases, investigators have started to explore less toxic conditioning therapies as an option to treat patients with impaired performance status and advanced disease. 5, 17 These trials have been preceded by animal models showing the possibility of sustained engraftment even after nonmyeloablative irradiation of the recipient. 18 ATG was used in the original series to intensify the pregrafting immunosuppression of the recipient to ensure engraftment. No graft failure was reported in 26 patients by Slavin et al. 5 We have now documented comparable results in a similar number of patients using 30 mg/m 2 less fludarabine and no ATG. One reason for the questionable role of ATG in the engraftment rate might be given by the pharmacokinetics of ATG with a half-life in serum of several days. 19 The antibodies not only target the recipient T cells but also bind to infused donor T cells, thereby leading to an unwanted T cell depletion of the graft. Predominating donor type chimerism for T and NK cells might be critical for tolerance of the graft. 4, 20 This increase of donor-type cellular immunity might be impaired by the infusion of ATG shortly before the transplant.
Complete chimerism is obtained in most patients with stable long-term engraftment. This statement can even be extended to apply to the CD34 positive compartment. 21 Recipient hematopoiesis is ablated by the combined effects of the busulphan application and the donor cytotoxic T cells which eliminate residual recipient progenitors. 22 As expected, the low early toxicity of the chemotherapy allowed us to treat older patients, as well as patients with extensive pretreatment or prior infectious complications. There was no toxic death associated with the chemotherapy applied, resulting in a 100 day survival of 95.2%. Most patients could be kept on oral alimentation throughout the whole treatment. Of note is the short duration of neutropenia and the low transfusion requirement achieved with this protocol. In contrast to the hematological recovery after intensive conditioning, the increase of platelet count preceded the neutrophil recovery in most patients.
We calculate the dose intensity reached by the use of 3.3 mg/kg busulphan ×2 and 30 mg/m 2 fludarabine ×5 to be about 50% of that of conventional conditioning therapy. In this respect, one has to keep in mind that the additional infusion of ATG is associated with a significant increase of side-effects of the conditioning therapy including anaphylactic reactions. 23 Although GVHD prophylaxis was stopped early in several patients in order to induce allogeneic graft-versustumor effects, no GVHD Ͼgrade II occurred and six patients could be treated successfully with steroids. So far, chronic GVHD has been observed in six out of 20 evaluable patients who had received unmanipulated PBSC.
CMV antigenemia was observed in six out of 24 patients, whereas two patients experienced CMV infection. This rate (33%) of CMV reactivation is similar to the data reported after allogeneic BMT using intensive conditioning therapy. 24 Data on the immunological recovery have to be collected prospectively in patients after dose-reduced conditioning therapy with or without ATG. Further aggravation of the cellular deficiency induced by ATG administration might be of special relevance, since older patients are prone to a delayed immune reconsitution. 25 Besides the unwanted clinical and immunological sideeffects associated with the administration of ATG, the argument for cost-effectiveness has to be discussed. Since the goal of dose-reduced conditioning is to treat older patients on an out-patient basis with reduced hospital costs, ATG should be omitted if similar clinical results can be achieved. Of course, this question can once again only be addressed in carefully designed randomized studies. One problem, when the question of prospective studies is addressed, is the fact that ATG preparations are difficult to compare because of some variation in biological activities between different product batches.
In summary, this study shows that purine analogue-containing conditioning therapy can achieve allogeneic engraftment in recipients of stem cell grafts from related HLA-matched donors without the use of ATG. The reduced toxicity of the regimen leads to a low early mortality compared to intensive conditioning therapy. Nevertheless significant acute and chronic GVHD may occur later after transplantation. Of course the follow-up is still short and the survival analysis has to be regarded with caution due to the low patient number and the heterogeneous patient population. Further studies have to explore the leukemiafree survival obtained with this approach compared to standard conditioning therapy. In patients with high-risk myeloid leukemia prophylactic donor leukocyte infusion is one way to improve the antileukemic effects of the procedure. Regular quantitative analysis of chimerism is important to detect imminent relapse earlier. Like other groups, we have observed antitumor responses associated with clinical GVHD in a patient with renal cell carcinoma. 26 Allogeneic immunotherapy seems to be most promising when performed at the stage of minimal residual disease. As described previously, patients with progressive or refractory leukemia are not likely to obtain durable remission.
